Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$12.32 USD

12.32
6,405,600

-0.31 (-2.45%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $12.30 -0.02 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax (NVAX) to Report Q3 Results: Wall Street Expects Earnings Growth

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax (NVAX) Gains As Market Dips: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $22.81, marking a +1.02% move from the previous day.

Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?

On Novavax's (NVAX) third-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.

Company News for Oct 21, 2022

Companies in The News Are: TSLA, T, ABB, MRNA, NVAX

Novavax (NVAX) Receives FDA Nod for COVID-19 Booster Jab

Novavax (NVAX) gets FDA authorization for using its COVID vaccine as a booster dose in adults after six months of completing the primary vaccine regimen.

Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More

Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax (NVAX) Reports Positive Data on COVID/FLU Combo Jab Study

Novavax (NVAX) reports positive data from its phase I/II study evaluating a combination of its COVID-19 and the seasonal influenza vaccine.

Novavax's (NVAX) COVID-19 Booster Recommended in Switzerland

The Federal Office of Public Health in Switzerland recommends Novavax's (NVAX) COVID-19 vaccine, Nuvaxovid, as a booster for both heterologous and homologous use in adults aged 18 years and older.

Why Novavax's (NVAX) COVID Vaccine Struggles for Market Share?

Despite being the first protein-based COVID-19 vaccine in many markets, Novavax's (NVAX) delayed product launch severely affected the company's prospects.

Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

Novavax (NVAX) closed the most recent trading day at $18.20, moving -1.99% from the previous trading session.

Why Novavax (NVAX) Stock Was Down 13% on Thursday

Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100.

The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax

Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.

Kinjel Shah headshot

Vaccine Stocks Down After Biden Says Pandemic is Over

BioNTech (BNTX), Moderna (MRNA) and Novavax (NVAX) stocks decline 8.6%, 7.1% and 6.5%, respectively.

Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax (NVAX) Flat As Market Sinks: What You Should Know

Novavax (NVAX) closed the most recent trading day at $32.55, making no change from the previous trading session.

Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More

Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.

Novavax (NVAX) Gets EU Nod for COVID-19 Booster Jab in Adults

Novavax (NVAX) gets authorization from the European Union to use its COVID-19 vaccine as a booster dose in adults.

Novavax (NVAX) Down 29.2% Since Last Earnings Report: Can It Rebound?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax's (NVAX) COVID-19 Jab Gets Approval in Switzerland

Novavax (NVAX) receives expanded temporary authorization for Nuvaxovid, its COVID-19 vaccine, in Switzerland for adolescents aged 12 to 17 and as a booster in adults aged 18 years and above.

Novavax's (NVAX) COVID-19 Booster Gets CHMP Recommendation

The European Medicines Agency's CHMP recommends expanded conditional marketing authorization for Novavax's (NVAX) COVID-19 vaccine as a booster for adults.

Ekta Bagri headshot

PFE, BNTX and MRNA Omicron Boosters Get Positive CHMP Opinion

Pfizer (PFE) /BioNTech (BNTX) and Moderna (MRNA) get positive CHMP opinion for Omicron-targeting bivalent booster.